Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ChromaDex Corporation
  6. Summary
    CDXC   US1710774076

CHROMADEX CORPORATION

(CDXC)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
2.065 USD   -1.20%
02/01ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs) Featuring Nicotinamide Riboside (NR)Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
AQ
01/31ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
BU
01/31ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators, Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
1.97(c) 1.96(c) 2.06(c) 2.09(c) 2.065(c) Last
234 273 849 811 351 348 246 600 333 565 Volume
-6.64% -0.51% +5.10% +1.46% -1.20% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 72,1 M - -
Net income 2022 -17,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,87x
Yield 2022 -
Sales 2023 85,7 M - -
Net income 2023 -8,18 M - -
Net Debt 2023 - - -
P/E ratio 2023 -19,7x
Yield 2023 -
Capitalization 154 M 154 M -
Capi. / Sales 2022 2,14x
Capi. / Sales 2023 1,80x
Nbr of Employees 115
Free-Float 54,8%
More Financials
Company
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products... 
Read more
More about the company
Ratings of ChromaDex Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CHROMADEX CORPORATION
02/01ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic..
AQ
01/31ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic..
BU
01/31ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic..
CI
01/18ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrat..
AQ
01/17ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrat..
BU
01/17ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrat..
CI
01/12ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm ..
BU
01/12ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board
CI
01/05Sector Update: Health Care Stocks Nudge Above Thursday Intra-Day Lows
MT
01/05Sector Update: Health Care Stocks Struggling Thursday but Biotech Edging H..
MT
01/05ChromaDex Names Brianna Gerber As CFO
MT
01/05Chromadex Corp. : Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
01/05ChromaDex Named Brianna Gerber Chief Financial Officer
BU
01/05Chromadex Corporation Names Brianna Gerber Chief Financial Officer
CI
2022ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementat..
AQ
More news
News in other languages on CHROMADEX CORPORATION
01/31ChromaDex partage les résultats prometteurs d'une étude clinique montrant que les activ..
01/17ChromaDex partage les résultats prometteurs d'une étude clinique, la première du genre,..
01/12ChromaDex nomme le Dr Vilhelm Bohr à son conseil consultatif scientifique
01/05Mise à jour sectorielle : Les actions du secteur des soins de sa..
01/05Mise à jour sectorielle : Les actions du secteur de la santé en ..
More news
Analyst Recommendations on CHROMADEX CORPORATION
More recommendations
ETFs positioned on CHROMADEX CORPORATIONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.02%4.70%United_States
More ETFs positioned on CHROMADEX CORPORATION
Chart CHROMADEX CORPORATION
Duration : Period :
ChromaDex Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHROMADEX CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 2,07 $
Average target price 5,73 $
Spread / Average Target 177%
EPS Revisions
Managers and Directors
Robert N. Fried Chief Executive Officer & Director
Brianna Gerber Chief Financial Officer
Steven D. Rubin Independent Non-Executive Director
Wing Tak Yu Independent Non-Executive Director
Gary Ng Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CHROMADEX CORPORATION22.92%154
MODERNA, INC.-1.82%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-3.32%28 711
SEAGEN INC.7.38%25 622